Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice-Reference-Cited by-同舟云学术

Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B‐cell lymphoma of the central nervous system – an international study of feasibility and efficacy in routine clinical practice

Published:2020-01-29 Issue:5 Volume:189 Page:879-887
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Schorb Elisabeth¹^ORCID,Fox Christopher P.²,Kasenda Benjamin³⁴,Linton Kim⁵,Martinez‐Calle Nicolas²,Calimeri Teresa⁶,Ninkovic Slavisa⁷^ORCID,Eyre Toby A.⁸^ORCID,Cummin Tom⁹,Smith Jeffery¹⁰,Yallop Deborah¹¹,De Marco Beatrice¹²,Krampera Mauro¹²,Trefz Stefan³,Orsucci Lorella¹³,Fabbri Alberto¹⁴,Illerhaus Gerald³,Cwynarski Kate⁷,Ferreri Andrés J. M.⁶

Affiliation:

1. Department of Hematology, Oncology and Stem Cell Transplantation Faculty of Medicine University of Freiburg Freiburg Germany

2. Department of Clinical Haematology Nottingham University Hospitals NHS Trust Nottingham United Kingdom

3. Department of Hematology Oncology and Palliative Care, Klinikum Stuttgart Stuttgart Germany

4. Department of Medical Oncology & Institute for Clinical Epidemiology and Biostatistics University Hospital Basel Basel Switzerland

5. Department of Medical Oncology The Christie NHS Foundation Trust Manchester United Kingdom

6. Lymphoma Unit Department of Onco‐Hematology IRCCS San Raffaele Scientific Institute Milan Italy

7. Department of Haematology University College London Hospital London United Kingdom

8. Department of Haematology Churchill Hospital Oxford United Kingdom

9. Cancer Research UK Cancer Sciences University of Southampton Southampton United Kingdom

10. Department of Clinical Haematology Aintree University Hospital Liverpool United Kingdom

11. Department of Haematological Medicine King's College Hospital London United Kingdom

12. Department of Medicine Section of Hematology University of Verona Verona Italy

13. San Giovanni Battista Hospital and University Turin Italy

14. Department of Oncology Division of Hematology Azienda Ospedaliera Universitaria Senese Siena Italy

Funder

Gilead Sciences

Roche

AbbVie

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16451

Reference21 articles.

1. Treatment for Primary CNS Lymphoma: The Next Step

2. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

3. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model

4. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002

5. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10;The Lancet Haematology;2024-07

2. Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance;eJHaem;2024-06-21

3. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-06

4. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up;HemaSphere;2024-06

5. Zanubrutinib plus Cytarabine in Patients with Refractory/Relapsed Primary Central Nervous System Lymphoma;Acta Haematologica;2024-02-26